Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

Orion Corporation, Orion Pharma29 enrolled

Overview

This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.

In July 2018 Norwegian authorities decided to allow switch at pharmacy for dry powder inhalers (DPIs) containing budesonide-formoterol. Pharmacists are instructed to switch patients to the inhaler with the lowest price. The pharmacist will train the patient on how to use the new inhaler. All patients whose eligible inhaler switch occurred between 1st July 2018 and 1st March 2019 will be eligible for the study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Asthma COPD

Interventions

Budesonide-FormoterolDRUG

Dry powder inhaler

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Written informed consent has been obtained. 2. Male or female patients with a diagnosis of asthma and/or COPD whose budesonide-formoterol DPI was switched to another budesonide-formoterol DPI at pharmacy between 1st July 2018 and 1st March 2019 (referred to as the eligible switch). 3. Age ≥12 years at time of switch. 4. Treated with budesonide-formoterol for at least 12 months before the eligible switch (pre-switch period) and 12 months after the eligible switch (post-switch period). Re-switch(es) of inhaler are allowed during the post-switch period. Exclusion Criteria: 1\. Patient has declined participation in the study or failed to respond to the invitation to participate.

Locations (1)

Flattum Legesenter

Hønefoss, Norway

Outcomes

Primary Outcomes

Disease control

The number of asthma and/or COPD exacerbations during the 12 months pre-switch and the 12 months post-switch.

Time frame: 24 months

Secondary Outcomes

Budesonide-formoterol dose

The change in the treatment dose of budesonide-formoterol at the time of the eligible switch and at the end of the post-switch period (e.g. 12 months post-switch).

Time frame: 24 months

Training at pharmacy

The correlation between inhaler training given at pharmacy and exacerbations.

Time frame: 24 months

Healthcare utilisation

The number of asthma and/or COPD related hospitalisations, emergency room visits and visits to physicians 12 months pre-switch and 12 months post-switch.

Time frame: 24 months

Inhaler switch

The number of re-switches after the first 'eligible' switch and the reasons for that switch.

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.